Kevin Croce, MD
Cardiovascular Disease · Chestnut Hill, MANPI 1417983172
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $986,473 of the $1,374,684 with a category attached, or 71.8%. 27 manufacturers reported payments, led by Abbott at 51.3% of the total. Among cardiovascular disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,091 payments — averaging $1260.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$705K
- Cardiovascular Systems Inc.$194K
- Boston Scientific$137K
- Shockwave Medical, Inc$119K
- Teleflex LLC$66K
- Philips North America LLC$63K
- plus $91K from 21 others
Across 423 payments — averaging $2048.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Arrow International, Inc.$252K
- Boston Scientific$157K
- Shockwave Medical, Inc$155K
- Cardiovascular Systems Inc.$129K
- Biotronik Inc.$113K
- Abiomed$19K
- plus $42K from 4 others
Across 1 payment — averaging $9500.00 each. An ownership or investment interest held by the physician or an immediate family member.
- Verge Medical, Inc.$10K
What the payments were for
- Consulting fees$986,47372%
- Speaking & faculty fees$250,10618%
- Travel & lodging$88,2546%
- Food & beverage$38,1033%
- Education$11,6421%
- Gifts$1060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 549 | $705,285 |
| Cardiovascular Systems Inc. | 110 | $193,723 |
| Boston Scientific | 113 | $136,687 |
| Shockwave Medical, Inc | 98 | $118,504 |
| Teleflex LLC | 43 | $66,059 |
| Philips North America LLC | 78 | $63,296 |
| Abiomed | 21 | $27,451 |
| Arrow International, Inc. | 18 | $22,210 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $9,900 |
| Terumo Medical Corporation | 9 | $7,764 |
| Biotronik Inc. | 6 | $6,194 |
| Vascular Solutions, Inc. | 3 | $5,997 |
| Cardinal Health 200 LLC | 2 | $5,500 |
| Asahi Intecc USA, Inc. | 9 | $2,974 |
| Spectrawave, Inc | 6 | $1,398 |
| Medtronic | 8 | $658 |
| Edwards Lifesciences | 2 | $386 |
| Corindus Inc. | 1 | $206 |
| Chiesi USA, Inc. | 1 | $107 |
| Reflow Medical Inc | 2 | $98 |
| W. L. Gore & Associates, Inc. | 1 | $89 |
| Amgen | 3 | $61 |
| Stryker | 2 | $54 |
| Cordis US CORP. | 1 | $31 |
| Avinger Inc. | 1 | $21 |
| Bracco Diagnostics Inc. | 1 | $20 |
| Teleflex Medical Canada Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIS$308,674
- Xience V coronary stent system$219,072
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$116,925
- Diamondback Coronary$90,724
- DRAGONFLY OPSTAR$89,668
- Dragonfly OCT$45,365
- Coronary Orbital Atherectomy System$43,482
- TURNPIKE$36,122
- (9520) IGT Devices Undivided$29,556
- AVVIGO Guidance System$28,329
- GUIDELINER$27,978
- Impella$27,198
- Vitalyst$19,771
- CLINICAL TRIAL PRODUCT$14,400
- Peripheral Orbital Atherectomy System$14,185
- XIENCE SKYPOINT$12,938
- CVX-300$11,448
- Diamondback Peripheral$11,006
- GENERAL - THERAPIES$8,414
- GUIDEWIRE: R350$7,200
How this compares
$1,374,684 in reported general payments places this provider in the 95th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $20,402 |
| Ranolazine ErRanolazine | 11 | $1,718 |
| ClopidogrelClopidogrel Bisulfate | 45 | $992 |
| Metoprolol Succinate | 34 | $799 |
| Atorvastatin Calcium | 50 | $643 |
| Lisinopril | 13 | $192 |
| Amlodipine Besylate | 17 | $80 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Chestnut Hill
- Marc SabatineBoston$3.9M
- Elizabeth NabelBoston$2.2M
- Kenneth RosenfieldBoston$1.4M
- James JanuzziBoston$1.1M
- Muthiah VaduganathanBoston$972K
- Joseph LoscalzoBoston$926K
- Sunil KapurBoston$823K
- Paul ZeiBoston$786K
- Paul RidkerBoston$572K
- Ignacio Inglessis-AzuajeBoston$545K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.